Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).
Leirisalo-Repo M, Kautiainen H, Laasonen L, Korpela M, Kauppi MJ, Kaipiainen-Seppänen O, Luosujärvi R, Luukkainen R, Karjalainen A, Blåfield H, Uutela T, Ilva K, Julkunen HA, Paimela L, Puolakka K, Moilanen E, Hannonen PJ, Möttönen T; NEO-RACo Study Group. Leirisalo-Repo M, et al. Among authors: luosujarvi r. Ann Rheum Dis. 2013 Jun;72(6):851-7. doi: 10.1136/annrheumdis-2012-201365. Epub 2012 Jun 30. Ann Rheum Dis. 2013. PMID: 22753402 Clinical Trial.
The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
Rantalaiho V, Korpela M, Hannonen P, Kautiainen H, Järvenpää S, Leirisalo-Repo M, Hakala M, Puolakka K, Julkunen H, Luosujärvi R, Möttönen T; FIN-RACo Trial Group. Rantalaiho V, et al. Among authors: luosujarvi r. Arthritis Rheum. 2009 May;60(5):1222-31. doi: 10.1002/art.24447. Arthritis Rheum. 2009. PMID: 19404945 Free article. Clinical Trial.
Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial.
Väänänen T, Vuolteenaho K, Kautiainen H, Nieminen R, Möttönen T, Hannonen P, Korpela M, Kauppi MJ, Laiho K, Kaipiainen-Seppänen O, Luosujärvi R, Uusitalo T, Uutela T, Leirisalo-Repo M, Moilanen E; NEO-RACo Study Group. Väänänen T, et al. Among authors: luosujarvi r. PLoS One. 2017 Aug 25;12(8):e0183294. doi: 10.1371/journal.pone.0183294. eCollection 2017. PLoS One. 2017. PMID: 28841649 Free PMC article. Clinical Trial.
How aggressive should initial therapy for rheumatoid arthritis be? The Finnish experience.
Kaarela K, Hakala M, Hannonen P, Kautiainen H, Korpela M, Leirisalo-Repo M, Luosujärvi R, Luukkainen R, Möttönen T, Puolakka K. Kaarela K, et al. Among authors: luosujarvi r. Rheumatology (Oxford). 2005 Jan;44(1):134-5; author reply 135-6. doi: 10.1093/rheumatology/keh394. Rheumatology (Oxford). 2005. PMID: 15611310 No abstract available.
Effectiveness of anakinra in rheumatic disease in patients naive to biological drugs or previously on TNF blocking drugs: an observational study.
Konttinen L, Kankaanpää E, Luosujärvi R, Blåfield H, Vuori K, Hakala M, Rantalaiho V, Savolainen E, Uutela T, Nordström D; ROB-FIN Study Group. Konttinen L, et al. Among authors: luosujarvi r. Clin Rheumatol. 2006 Nov;25(6):882-4. doi: 10.1007/s10067-006-00243-0. Epub 2006 Mar 22. Clin Rheumatol. 2006. PMID: 16552464
31 results